hVIVO to present at Jefferies Global Healthcare Conference
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that Yamin ‘Mo’ Khan, Chief Executive Officer, will be presenting in-person at the Jefferies Global Healthcare Conference in London on 20 November 2025 at 12.30pm GMT. Alongside the presentation, the Company will also be available for one-to-one meetings.
The Jefferies Global Healthcare Conference is the largest healthcare-dedicated conference in Europe and is taking place between the 17-20 November 2025 in London. The conference hosts over 700 healthcare companies, 3,600 attendees, and 10,000 investor and business-to-business meetings. The event brings together C-suite executives from leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.
No new material information will be disclosed during the day and the PDF of the presentation will be made available on the Company’s website shortly after the event.
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 |
|||
|
Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
||||
Notes to Editors
hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.
hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.
Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.
The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
